Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTRONE vs AMNESTROGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (off-label in some contexts),Prostate cancer (palliative therapy, off-label),Breast cancer (palliative therapy in selected cases, off-label)
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of vulvar and vaginal atrophy due to menopause,Prevention of postmenopausal osteoporosis,Estrogen replacement therapy in female hypogonadism,Palliative treatment of advanced breast cancer in selected postmenopausal women,Palliative treatment of advanced prostate cancer
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
Terminal elimination half-life is 13-18 hours; steady-state achieved after 5-7 days.
Metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation to glucuronides and sulfates. Estrone is interconvertible with estradiol and estriol. Enterohepatic recirculation occurs.
Hepatic metabolism via cytochrome P450 enzymes (CYP3A4 and others); undergoes enterohepatic recirculation.
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Primarily renal (90-95%) as glucuronide and sulfate conjugates; biliary/fecal elimination accounts for <5%.
Approximately 96-98% bound to albumin and sex hormone-binding globulin (SHBG)
98% bound primarily to albumin and sex hormone-binding globulin (SHBG).
0.8-1.2 L/kg; indicates extensive distribution into tissues, particularly adipose tissue.
1.0-1.5 L/kg; indicates extensive tissue distribution and binding.
Oral: ~5% due to extensive first-pass metabolism; Intramuscular: 100%; Topical: variable, approximately 10% systemically.
Oral: 2-10% due to first-pass metabolism; IM: 100%; Transdermal: 5-15%; Vaginal: 5-25%.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of metabolites; monitor estrogenic effects.
No specific dose adjustment required; use with caution in severe impairment (e GFR <30 m L/min/1.73m²) due to potential fluid retention
Contraindicated in severe hepatic impairment (Child-Pugh class C). In Child-Pugh class A or B, reduce dose by 50% and monitor liver function; start at lowest effective dose.
Contraindicated in Child-Pugh class B and C; for class A, use lowest effective dose with monitoring
Not indicated for routine use; individualize for rare conditions (e.g., delayed puberty) under specialist guidance. Typical starting dose: 0.3-0.625 mg orally once daily; adjust based on response and bone age.
Not indicated for pediatric use; safety and efficacy not established
Start at low end of dosing range (e.g., 0.3-0.625 mg orally once daily); consider increased risk of thromboembolism and endometrial cancer; monitor for adverse effects; use shortest duration possible.
Use lowest effective dose for shortest duration; increased risk of stroke, dementia, and breast cancer; consider alternative therapies
Estrogens increase the risk of endometrial cancer in postmenopausal women. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Estrogens increase the risk of endometrial cancer in postmenopausal women with an intact uterus. Estrogen-progestin therapy increases the risk of cardiovascular events, breast cancer, and probable dementia. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis.
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction, especially in smokers and older women,Malignancy: Increased risk of endometrial cancer (unopposed estrogen) and potential for breast cancer; avoid use in known or suspected estrogen-dependent neoplasia,Dementia: Possible increased risk in women over 65 years,Gallbladder disease: Increased risk of cholelithiasis,Hypertriglyceridemia: May cause severe hypertriglyceridemia with pancreatitis,Hepatic impairment: Use with caution; may be contraindicated in severe disease,Fluid retention: May exacerbate conditions such as asthma, epilepsy, migraine, cardiac or renal dysfunction,Hypocalcemia: Should be used with caution in patients with hypoparathyroidism,Visual abnormalities: Discontinue if sudden vision loss, proptosis, or migraine develops
Cardiovascular disorders (stroke, MI, thromboembolism), malignant neoplasms (endometrial cancer, breast cancer), probable dementia (use >65 years), gallbladder disease, hypercalcemia, visual abnormalities, elevated blood pressure, hereditary angioedema, hypertriglyceridemia, fluid retention, hypothyroidism, exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, SLE, hepatic hemangiomas, and conditions aggravated by fluid retention.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except in selected palliative cases),Known or suspected estrogen-dependent neoplasia,Active or history of venous thromboembolism (e.g., DVT, pulmonary embolism),Active arterial thromboembolic disease (e.g., stroke, MI),Severe hepatic impairment or disease,Hypersensitivity to estrone or any component of the formulation
Known or suspected pregnancy, undiagnosed abnormal genital bleeding, known or suspected breast cancer (except selected patients), known or suspected estrogen-dependent neoplasia, active DVT/PE or history of thromboembolic disorders, known protein C, protein S, or antithrombin deficiency, known thrombophilic disorders, active or recent arterial thromboembolic disease (e.g., stroke, MI), known liver impairment or disease, known hypersensitivity to any ingredient.
Grapefruit and grapefruit juice may inhibit estrone metabolism, increasing serum levels and risk of adverse effects. Avoid concomitant high-fat meals as they may alter absorption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
Grapefruit and grapefruit juice may increase estrogen levels; avoid large amounts. No significant food interactions reported but take with or without food consistently to maintain stable absorption.
First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tract abnormalities and potential for other adverse effects. Overall: FDA Pregnancy Category X (contraindicated) unless used for specific conditions like progesterone-resistant recurrent pregnancy loss.
First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalities, feminization of male fetus, and potential long-term reproductive effects. Use contraindicated in pregnancy.
Estrone is excreted in human breast milk; M/P ratio not determined. Use during lactation is generally contraindicated as estrogens may suppress milk production and alter milk composition. Alternative agents recommended if breastfeeding.
Contraindicated during breastfeeding. Amnestrogen is excreted in breast milk; M/P ratio unknown. Potential for serious adverse effects in nursing infants including hormonal disruption.
No recommended dosing in pregnancy due to contraindication; if used, no established dose adjustments exist. Estrogen clearance is increased in pregnancy, but systematic data for estrone are lacking; generally, avoidance is advised.
Not applicable as drug is contraindicated in pregnancy. No dose adjustment recommended due to avoidance of use.
Estrone is primarily used in menopausal hormone therapy and has weak estrogenic activity compared to estradiol. Monitor for endometrial hyperplasia in women with an intact uterus; concurrent progestin is required. Assess thromboembolic risk before initiation. Estrone may be less effective for vasomotor symptoms than estradiol. Avoid in patients with breast cancer, liver disease, or undiagnosed vaginal bleeding.
Amnestrogen (estrogen-progestin combination) is used for hormone replacement therapy. Monitor for thromboembolic events; avoid in patients with history of DVT/PE. Use lowest effective dose for shortest duration. Not for use in pregnancy; contraindicated in breast cancer. May increase risk of endometrial cancer if used without progestin in women with intact uterus.
Take estrone exactly as prescribed; do not alter dose or frequency.,Report any unusual vaginal bleeding, breast lumps, or jaundice immediately.,Estrone does not protect against HIV or other sexually transmitted infections.,You may experience nausea, headache, or breast tenderness; contact your doctor if severe.,Do not use estrone if you are pregnant, think you might be pregnant, or are breastfeeding.,Avoid smoking and excessive alcohol consumption to reduce cardiovascular risks.
Take exactly as prescribed; do not skip doses.,Report immediately any signs of blood clots: sudden leg pain, chest pain, shortness of breath, or vision changes.,Avoid smoking while on this medication; increases clot risk.,Do not use during pregnancy; if pregnancy occurs, stop and contact doctor.,Regular breast exams and mammograms are recommended.,May cause nausea; take with food or at bedtime.
"Almasilate, a magnesium-aluminum antacid, can adsorb estrone in the gastrointestinal tract, reducing its absorption and systemic bioavailability. This interaction may lead to subtherapeutic estrone levels, potentially diminishing its therapeutic effects in hormone replacement therapy. Patients may experience inadequate symptom control or hormonal imbalance if the drugs are taken concomitantly without proper timing separation."
"Clarithromycin is a potent CYP3A4 inhibitor and also inhibits P-glycoprotein, significantly decreasing the clearance of estrone, which is metabolized via CYP3A4 and transported by P-gp. This leads to elevated estrone plasma concentrations, increasing estrogenic effects such as thromboembolic risk, breast tenderness, and endometrial proliferation. Clinical vigilance is warranted, especially in patients on hormone replacement therapy or using estrone for menopausal symptoms, as coadministration may precipitate estrogen-related adverse events."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTRONE vs AMNESTROGEN, answered by our medical review team.
ESTRONE is a Estrogen that works by Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.. AMNESTROGEN is a Estrogen that works by Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription and promoting development and maintenance of female reproductive tissues and secondary sex characteristics.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTRONE and AMNESTROGEN depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTRONE is: For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.. The standard adult dose of AMNESTROGEN is: 1 tablet (2.5 mg estradiol and 0.625 mg norgestimate) orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTRONE and AMNESTROGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTRONE is classified as Category C. First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tra. AMNESTROGEN is classified as Category C. First trimester: Increased risk of congenital anomalies including cardiovascular defects and neural tube defects. Second and third trimesters: Risk of urogenital tract abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.